Patients must meet the following criteria to be eligible for CAR T-Cell Immunotherapy: Patient is well enough to receive CAR T-Cell Immunotherapy. Tumour has expressed the appropriate marker, e.g. CD19. An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Absence of disease complications or chemo-toxicity; such as, infection, active GVHD, hyperleucocytosis, severe...
Cytopenia – Cytopenia occurs when one or more of the blood cell types are lower than it should be. Blood consists of red blood cells which carry oxygen and nutrients around the body, and white blood cells which fight infection. B-Cell Aplasia – B-Cell aplasia occurs when anti-CD19 CAR T-Cells kill normal B lymphocytes that...
T-Cell Cryopreservation Option If any of the above requirements are not met for the patient to be eligible to undergo the CAR T-Cell immunotherapy for the time being, there is an option for the patient to freeze their T- Cells for future use once treatment can proceed.
Pre-assessment – Up to 4 weeks. Pre-treatment phase (apheris, CAR T-Cell manufacturing, conditioning chemotherapy) – Up to 6 weeks. Treatment (CAR T-Cell infusion, monitoring) – Up to 1 week. Post-treatment Monitoring (follow up) – Up to 24 weeks. Disclaimer: The actual immunotherapy treatment process is dependent on individual patients and the type of cancer.
Sign up for you and your loved ones to receive the latest news and updates about CAR T-Cell Immunotherapy.
